Neonc Technologies Holdings, Inc.
NTHIHealthcare|Biotechnology|US
$3.49
+0.29 (+9.06%)
Cash / Share
$0.24
About
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Stock Price
-64.6%(1Y)
1M
+37.9%
3M
-0.3%
6M
-36.0%
YTD
-57.8%
1Y
-65.6%
3Y
-63.8%
5Y
-63.8%
Pipeline Summary
4 total trials3
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 3Active: 1
Active Trials (4)
NEO100 and High-Grade Meningioma
NCT05023018Residual, Progressive or Recurrent Grade II or III Meningioma
Phase 2Recruiting
Enrollment: 30 participants
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379Diffuse Astrocytoma, IDH-Mutant
Phase 1Phase 2Recruiting
Enrollment: 134 participants
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
NCT06357377Pediatric Tumor of CNS
Phase 1Recruiting
Enrollment: 12 participants
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
NCT02704858Glioblastoma Multiforme
Phase 1Phase 2Active
Enrollment: 49 participants
Key Facts
Market Cap$100.5M
Employees5
CEOAmir Farrokh Heshmatpour
IPO DateMar 26, 2025
Beta0.50
52-Week Range$2.5 – $12
Avg Volume171,232
ExchangeNASDAQ
Websiteneonctech.com
Ownership
Float22.1%
Shares Outstanding28.8M
Recent Insider Trades
ALABEDIN ALI MOHAMMAD AHMAD MOHAMMADOTHER
Oct 9, 20260 shares
GARNETT KEITHLYSELL
Sep 15, 20265,000 shares @ $3.36
Heshmatpour Amir FBUY
Sep 15, 202635,000 shares @ $3.30
Heshmatpour Amir FBUY
Sep 14, 202615,000 shares @ $3.96
CHEN THOMAS CBUY
Sep 14, 20265,242 shares @ $3.81
Recent News
NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Nov 5, 2026 · globenewswire.com
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage
Nov 2, 2026 · globenewswire.com
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
Nov 2, 2026 · globenewswire.com
NeOnc's Ambitious Brain Cancer Plans are Setting the Stage
Oct 30, 2026 · globenewswire.com
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
Oct 26, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:25 AM